Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
-
Published:2023-12-15
Issue:
Volume:
Page:
-
ISSN:0007-0920
-
Container-title:British Journal of Cancer
-
language:en
-
Short-container-title:Br J Cancer
Author:
Font AlbertORCID, Mellado Begona, Climent Miguel A., Virizuela Juan Antonio, Oudard Stephane, Puente Javier, Castellano Daniel, González-del-Alba Aranzazu, Pinto Alvaro, Morales-Barrera Rafael, Rodriguez-Vida Alejo, Fernandez Pedro L., Teixido Cristina, Jares Pedro, Aldecoa Iban, Gibson Neil, Solca Flavio, Mondal Shoubhik, Lorence Robert M., Serra Josep, Real Francisco X.ORCID
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference44 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. 2. Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol. 2008;10:31–43. 3. Vishnu P, Mathew J, Tan WW. Current therapeutic strategies for invasive and metastatic bladder cancer. Oncol Targets Ther. 2011;4:97–113. 4. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–77. 5. Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012;23:406–10.
|
|